Literature DB >> 21833986

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Milo Puhan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21833986     DOI： 10.1002/14651858.ED000028

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


× No keyword cloud information.
  3 in total

1.  Roflumilast: a green signal is yet to come.

Authors:  Nazir Lone; Yuji Oba
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  Benefits and harms of roflumilast in moderate to severe COPD.

Authors:  Tsung Yu; Kevin Fain; Cynthia M Boyd; Sonal Singh; Carlos O Weiss; Tianjing Li; Ravi Varadhan; Milo A Puhan
Journal:  Thorax       Date:  2013-12-17       Impact factor: 9.139

3.  Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.

Authors:  Milo A Puhan; Tsung Yu; Cynthia M Boyd; Gerben Ter Riet
Journal:  BMC Med       Date:  2015-07-02       Impact factor: 8.775
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.